Type2 diabetes mellitus
Conditions
Interventions
Patients with type 2 diabetes mellitus with inadequate glycemic control who are taking diet and exercise or oral hypoglycemic agents other than SGLT2 inhibitors will receive luseogliflozin 2.5 mg/day
Sponsors
Department Internal Medicine of Diabetes, Hematology and Collagen Diseases,Moji Medical Center, Kyushu Rosai Hospital, Japan Labor Healthand Safety Organization
The First Department of Internal Medicine, University of Occupational and Environmental Health, Japan
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Patients who meet all of the following criteria will be eligible. (1) Age 20 years or older, 89 years or younger (regardless of gender) (2) Patients with an HbA1c of 7.0% or higher (3) Patients who can give their consent to participate in this study.
Exclusion criteria
Exclusion criteria: (1) Patients on insulin (2) Pregnant women or women who may be pregnant (3) Patients with a history of hypersensitivity to luseogliflozin (4) Pregnant women or women who may be pregnant, women who wish to become pregnant, and women who are breast-feeding (5) Others who are judged by the investigator to be inappropriate for this study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Change in HbA1c before and after luseogliflozin administration (2.5 mg/day, 5 mg/day) | — |
Secondary
| Measure | Time frame |
|---|---|
| Changes in (fasting) blood glucose, (fasting )insulin, triglycerides, LDL-cholesterol, HDL-cholesterol, eGFR, uric acid, AST, ALT, ganma-GTP, DBP, and SBP before and after luseogliflozin administration (2.5 mg/day, 5 mg/day) | — |
Countries
Japan
Contacts
Public ContactTadashi Arao
Moji Medical Center, Kyushu Rosai Hospital, Japan Labor Health and Safety Organization Department Internal Medicine of Diabetes, Hematology and Collagen Diseases
Outcome results
None listed